Evaluation of the relationship between the mean platelet volume and the neutrophil/lymphocyte ratio with progression of chronic kidney disease in patients with autosomal dominant polycystic kidney disease.

C-reactive protein inflammation mean platelet volume polycystic kidney disease

Journal

Northern clinics of Istanbul
ISSN: 2536-4553
Titre abrégé: North Clin Istanb
Pays: Turkey
ID NLM: 101684520

Informations de publication

Date de publication:
2022
Historique:
received: 16 06 2021
accepted: 02 08 2021
entrez: 24 10 2022
pubmed: 25 10 2022
medline: 25 10 2022
Statut: epublish

Résumé

Increased inflammation is known to cause higher mortality and morbidity in autosomal dominant polycystic kidney disease (ADPKD). At the same time, inflammation has been shown to contribute in chronic kidney disease (CKD) progression pathogenesis. Neutrophil-lymphocyte ratio (NLR) and mean platelet volume (MPV) have been lately found to be related with systemic inflammation. Therefore, in this study, it was intended to evaluate any correlation between the NLR and MPV degree and poor prognosis in ADPKD patients. The study sample comprised 86 adult patients (male: 80.2%, mean age: 35.35 years) screened in the Nephrology Outpatient Clinic with the diagnosis of ADPKD. Data were obtained from the electronic database of the hospital. Two groups were made from the patients: Group I included ADPKD patients with CKD Stages I-II and Group II included ADPKD patients with CKD Stages III-V. The relationships between CKD stage and laboratory parameters were analyzed. Significantly higher NLR (2.64±1.43 vs. 2.02±0.89, p=0.024), MPV (9.84±1.65 vs. 9.08±1.17, p=0.045), and hs-CRP (10.7±2.2 vs. 22.4±8.3, p=0.001) values were determined in Group II than in those with Group I. Positive correlations were statistically significative observed between hs-CRP and MPV and NLR in the patients with ADPKD. The study results demonstrated that significantly NLR and MPV are increased in ADPKD patients with progression of CKD. Therefore, lowering the NLR and MPV level could be new, therapeutic, and preventive alternatives for patients with ADPKD.

Identifiants

pubmed: 36276574
doi: 10.14744/nci.2021.89657
pii: NCI-9-317
pmc: PMC9514079
doi:

Types de publication

Journal Article

Langues

eng

Pagination

317-322

Informations de copyright

© Copyright 2022 by Istanbul Provincial Directorate of Health.

Déclaration de conflit d'intérêts

No conflict of interest was declared by the author.

Références

Nat Rev Nephrol. 2009 Apr;5(4):221-8
pubmed: 19322187
Clin J Am Soc Nephrol. 2011 Jan;6(1):7-13
pubmed: 20829421
Int Urol Nephrol. 2015 Jul;47(7):1187-94
pubmed: 26047596
Kidney Blood Press Res. 2002;25(2):103-8
pubmed: 12077492
Lancet. 1994 Apr 2;343(8901):824-7
pubmed: 7908078
Ann Intern Med. 2004 Jan 6;140(1):9-17
pubmed: 14706967
JAMA. 2004 Jan 28;291(4):451-9
pubmed: 14747502
Thromb Haemost. 1987 Aug 4;58(2):714-7
pubmed: 3672422
Kidney Int. 2005 Jul;68(1):237-45
pubmed: 15954913
Lancet. 2010 Apr 10;375(9722):1287-95
pubmed: 20382325
Am J Kidney Dis. 2002 Feb;39(2 Suppl 1):S1-266
pubmed: 11904577
Clin Nephrol. 2016 Apr;85(4):199-208
pubmed: 26521887
J Investig Med. 2013 Mar;61(3):597-603
pubmed: 23360844
J Am Soc Nephrol. 2001 Jan;12(1):194-200
pubmed: 11134267
Platelets. 2014;25(4):274-8
pubmed: 23772896
Hemodial Int. 2013 Jul;17(3):391-6
pubmed: 23522328
Kidney Int. 1997 Dec;52(6):1497-510
pubmed: 9407495
J Intern Med. 1990 Jan;227(1):11-4
pubmed: 2299294
Int J Clin Exp Med. 2014 Jul 15;7(7):1794-801
pubmed: 25126182
N Engl J Med. 1993 Jul 29;329(5):332-42
pubmed: 8321262
Indian J Nephrol. 2013 Jan;23(1):34-40
pubmed: 23580803
Br Med J (Clin Res Ed). 1983 Aug 13;287(6390):456-9
pubmed: 6411172
Kidney Int Suppl. 1997 Dec;63:S93-7
pubmed: 9407432
Clin Exp Nephrol. 2013 Aug;17(4):532-40
pubmed: 23180042
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839

Auteurs

Mahmut Gok (M)

Department of Nephrology, Sultan Abdulhamid Han Training and Research Hospital, Istanbul, Turkiye.

Classifications MeSH